|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | How to assess the efficacy or failure of targeted therapy:deciding when to stop sorafenib in hepatocellular carcinoma显示文摘Sorafenib is thus far the only systemic treatment for hepatocellular carcinoma(HCC) based on the results of two randomized controlled trials performed in Western and in Eastern countries, despite a poor response rate(from 2% to 3.3%) following conventional evaluation criteria. It is now recognized that the criteria(European Association of the Study of the Liver criteria, modified response evaluation criteria in solid tumors) based on contrast enhanced techniques(computed tomography scan, magnetic resonance imaging) aimed to assess the evolution of the viable part of the tumor(hypervascularized on arterial phase) are of major interest to determine the efficacy of sorafenib and of most antiangiogenic drugs in patients with HCC. The role of alphafetoprotein serum levels remains unclear. In 2016, in accordance with the SHARP and the Asia-Pacific trials, sorafenib must be stopped when tolerance is poor despite dose adaptation or in cases of radiological and symptomatic progression. This approach will be different in cases of available second-line therapy trials. Some recent data(in renal cell carcinoma) revealed that despite progression in patients who received sorafenib, this drug can still decrease tumor progression compared to drug cessation. Then, before deciding to continue sorafenib post-progression or shift to another drug, knowing other parameters of post-progression survival(Child-Pugh class, Barcelona Clinic Liver Cancer, alphafetoprotein, post-progression patterns in particular, the development of extrahepatic metastases and of portal vein thrombosis) will be of major importance. | Jean-Luc Raoul Xavier Adhoute Marine Gilabert Julien Edeline | 2016 | World Journal of Hepatology2016，8，35： | 8 |
| 2 | Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments显示文摘Therapeutic management of hepatocellular carcinoma(HCC) is quite complex owing to the underlying cirrhosis and portal vein hypertension. Different scores or classification systems based on liver function and tumoral stages have been published in the recent years. If none of them is currently 'universally' recognized, the Barcelona Clinic Liver Cancer(BCLC) staging system has become the reference classification system in Western countries. Based on a robust treatment algorithm associated with stage stratification, it relies on a high level of evidence. However, BCLC stage B and C HCC include a broad spectrum of tumors but are only matched with a single therapeutic option. Some experts have thus suggested to extend the indications for surgery or for transarterial chemoembolization. In clinical practice, many patients are already treated beyond the scope of recommendations. Additional alternative prognostic scores that could be applied to any therapeutic modality have been recently proposed. They could represent complementary tools to the BCLC staging system and improve the stratification of HCC patients enrolled in clinical trials, as illustrated by the NIACE score. Prospective studies are needed to compare these scores and refine their role in the decision making process. | Xavier Adhoute Guillaume Penaranda Jean Luc Raoul Patrice Le Treut Emilie Bollon Jean Hardwigsen Paul Castellani Hervé Perrier Marc Bourlière | 2016 | World Journal of Hepatology2016，8，17： | 7 |
| 3 | Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?显示文摘Several hepatocellular carcinoma(HCC) staging systems have been established, and a variety of countryspecific treatment strategies are also proposed. The barcelona- clinic liver cancer(BCLC) system is the most widely used in Europe. The Hong Kong liverCancer is a new prognostic staging system; it might become the reference system in Asia. Transarterial chemoembolization(TACE) is the most widely used treatment for HCC worldwide; but it showed a benefit only for intermediate stage HCC(BCLC B), and there is still no consensus concerning treatment methods and treatment strategies. In view of the highly diverse nature of HCC and practices, a scoring system designed to assist with decision making before the first TACE is performed or prior to repeating the procedure would be highly useful. | Xavier Adhoute Guillaume Penaranda Paul Castellani Herve Perrier Marc Bourliere | 2015 | World Journal of Hepatology2015，7，3： | 6 |
| 4 | Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations显示文摘 | Juliette Foucher Laurent Castéra Pierre-Henri Bernard Xavier Adhoute David Laharie Julien Bertet Patrice Couzigou Victor de Lédinghen | 2006 | European Journal of Gastroenterology & Hepatology2006，，4： | 3 |
| 5 | Is liver SUV stable o ver time in ^18F-FDG PET Imaging? 显示文摘 | Laffon E Adhoute X de Clermont H | 2011 | J Nucl Med Technol2011，39，4： | 1 |
| 6 | Diagnosis of cirrhosis by transient elastography (FibroScan):a prospective study显示文摘 | Foucher J Chanteloup E Vergniol J Castera L Le Bail B Adhoute X | | Gut0，，： | 1 |
| 7 | Diagnosis of liver fibrosis by transient elastography(FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate显示文摘 | Laharie D Zerbib F Adhoute X | 2006 | Alimentary Pharmacology & Therapeutics2006，23，11： | 1 |
| 8 | Dignosis of liver fibrosis bytransient elastography(FibroScan) and non-invasive methods inCrohn's diseases pationts treated with methotrexate显示文摘 | Laharie D Zerbib F Adhoute X | 2006 | Aliment Pharmacol Ther2006，23，： | 1 |
| 9 | Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort显示文摘AIM To compare the performances of the Barcelona clinic liver cancer(BCLC) nomogram and others systems(BCLC, HKLC, CLIP, NIACE) for survival prediction in a large hepatocellular carcinoma(HCC) French cohort.METHODS Data were collected retrospectively from 01/2007 to 12/2013 in five French centers. Newly diagnosed HCC patients were analyzed. The discriminatory ability, homogeneity ability, prognostic stratification ability Akaike information criterion(AIC) and C-index were compared among scoring systems. RESULTS The cohort included 1102 patients, mostly men, median age 68 [60-74] years with cirrhosis(81%), child-Pugh A(73%), alcohol-related(41%), HCV-related(27%). HCC were multinodular(59%) and vascular invasion was present in 41% of cases. At time of HCC diagnosis BCLC stages were A(17%), B(16%), C(60%) and D(7%). First line HCC treatment was curative in 23.5%, palliative in 59.5%, BSC in 17% of our population. Median OS was 10.8 mo [4.9-28.0]. Each system distinguished different survival prognosis groups(P < 0.0001). The nomogram had the highest discriminatory ability, the highest C-index value. NIACE score had the lowest AIC value. The nomogram distinguished sixteen different prognosis groups. By classifying unifocal large HCC into tumor burden 1, the nomogram was less powerful. CONCLUSION In this French cohort, the BCLC nomogram and the NIACE score provided the best prognostic information, but the NIACE could even help treatment strategies. | Xavier Adhoute Guillaume Pénaranda Jean Luc Raoul Julien Edeline Jean-Frédéric Blanc Bernard Pol Manuela Campanile HervéPerrierO livier Bayle Olivier Monnet Patrick Beaurain Cyril Muller Paul Castellani Yves Patrice Le Treut Jean Pierre Bronowicki Marc Bourlière | 2017 | World Journal of Gastroenterology2017，23，14： | 1 |
| 10 | Hepatocellular carcinoma scoring and staging systems. Do we need new tools?显示文摘 | Xavier Adhoute Guillaume Penaranda Jean Luc Raoul Marc Bourlière | 2016 | Journal of Hepatology2016，，： | 1 |
| 11 | Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process显示文摘 | Xavier Adhoute Guillaume Penaranda Sebastien Naude Jean Luc Raoul Herve Perrier Olivier Bayle Olivier Monnet Patrick Beaurain Christophe Bazin Bernard Pol Gaelle Le Folgoc Paul Castellani Jean Pierre Bronowicki Marc Bourlière | 2014 | Journal of Hepatology2014，，： | 1 |
| 12 | Usefulness of HKLC versus BCLC staging system in a European HCC cohort显示文摘 | Xavier Adhoute Guillaume Penaranda Jean-Pierre Bronowicki Jean-Luc Raoul | 2014 | Journal of Hepatology2014，，： | 1 |
| 13 | Diagnosis of liver fibrosis by transient elastography(Fibroscan) and noninvasive methods in Crohn's disease patients treated with methotrexate 显示文摘 | LAHARIE D ZERBIB F ADHOUTE X | 2006 | Aliment Pharmacol Ther2006，23，： | 1 |
| 14 | 晚期胰腺癌放化疗后的局部切除显示文摘Objectives-The aim of this study was to evaluate the possibility of subsequent resection of locally advanced pancreatic adenocarcinoma after chemotherapy and external-beam radiotherapy.Patients and methods-Between January 1996 and January 2001,33 consecutive patients(18 males and 15 women,mean age 63 years)with locally advanced PA were treated with chemotherapy and concurrent external-beam radiotherapy.Radiotherapy delivered 45-50.4Gy,in a classical manner(N= 27)or on a split course(N = 6).Chemotherapy was made of 5FU by continuous infusion for all patients during 5 weeks and cisplatin at the 1st and 5 weeks(N = 22).Tumor resectability was reassessed at the end of the chemoradiotherapy;surgical resection of tumour was attempted in patients whose tumor demonstrated reduction in size,and supplementary radiotherapy of 10 to 15 Gy was delivered to the others.Results-Thirty-nine percent of patients experienced grade 3 acute toxicity.WHO criteria response to chemoradiotherapy four weeks after the end of treatment were:4 partial responders(12%),6 minor responders(18%),14 stable disease(42%),9 progression(28%).Ten patients underwent exploratory laparotomy,in one case vascular encasement did not allow for tumor resection,and in another patient,there was peritoneal carcinomatosis.In the 8 remaining patients,surgical(RO)resection was possible.In one patient histological examination showed fibrosis with no residual tumour.After a median follow-up period of 40 months,median survival was 16 months(66%and 37%of survival at 1 and 2 years respectively).In operated and non-operated patients,survival rates at 24 months were 73%and 12.5%respectively.At 1 year,80%of the patients treated with radiochemotherapy developed recurrence,metastatic recurrence in 88%.Initial laparotomy,split course radiotherapy were poor outcome factors whereas chemotherapy appears to be a favorable outcome factor.Conclusion-Subsequent resection of locally advanced pancreatic adenocarcinoma is possible after chemoradiotherapy allowing for a prolonged survival in some patients. | Adhoute X. Smith D. Vendrely V. V.De Lédinghen 张诗峰 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，9： | 0 |
| 15 | Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib:Multicenter French clinical experience in real-life after matching显示文摘BACKGROUND Starting a second-line systemic treatment for hepatocellular carcinoma(HCC)is a common situation.The only therapeutic options in France are two broadspectrum tyrosine kinase inhibitors(TKIs),regorafenib(REG)and cabozantinib(CBZ),but no comparative real-life studies are available.AIM To evaluate the progression-free survival(PFS)of patients treated with REG or CBZ,we investigated the disease control rate(DCR),overall survival(OS),and safety of both drugs.To identify the variables associated with disease progression over time.METHODS A retrospective multicenter study was performed on the clinical data of patients attending one of three referral centers(Avignon,Marseille,and Nice)between January 2017 and March 2021 using propensity score matching.PFS and OS were assessed using the Kaplan-Meier method.Multivariate analysis(MA)of progression risk factors over time was performed in matched-pair groups.RESULTS Fifty-eight patients 68(62-74)years old with HCC,Barcelona clinic liver cancer(BCLC)B/C(86%),Child-Pugh(CP)-A/B(24%)received REG for 3.4(1.4-10.5)mo as second-line therapy.Twentyeight patients 68(60-73)years,BCLC B/C(75%),CP-A/B(25%)received CBZ for 3.7(1.8-4.9)mo after first-line treatment with sorafenib[3(2-4)(CBZ)vs 4(2.9-11.8)mo(REG),P=0.0226].Twenty percent of patients received third-line therapy.After matching,PFS and DCR were not significantly different after a median follow-up of 6.2(2.7-11.7)mo(REG)vs 5.2(4-7.2)mo(CBZ),P=0.6925.There was no difference in grade 3/4 toxicities,dose reductions,or interruptions.The OS of CP-A patients was 8.3(5.2-24.8)vs 4.9(1.6-11.7)mo(CP-B),P=0.0468.The MA of risk factors for progression over time identified C-reactive protein(CRP)>10 mg/L,neutrophil-to-lymphocyte ratio(NLR)>3,and aspartate aminotransferase(AST)>45 IU as predictive factors.CONCLUSION This multicenter indirect comparative study found no significant difference in PFS between REG and CBZ as second-line therapy for advanced HCC.Elevated levels of inflammatory markers(CRP and NLR)and AST were associated with non-control of TKIs over time.A 2-mo online progression risk calculation is proposed. | Xavier Adhoute Marie De Matharel Laurent Mineur Guillaume Pénaranda Dann Ouizeman Clemence Toullec Albert Tran Paul Castellani Armelle Rollet Valérie Oules HervéPerrier Si Nafa Si Ahmed Marc Bourliere Rodolphe Anty | 2022 | World Journal of Gastrointestinal Oncology2022，14，8： | 0 |
| 16 | Usefulness of the MESH score in a European hepatocellular carcinoma cohort显示文摘The Barcelona Clinic Liver Cancer classification is the most widely-used hepatocellular carcinoma(HCC) staging system because it is simple,precise and linked to a treatment algorithm based on randomized studies.But each group includes a broad spectrum of tumors,with limited therapeutic options,particularly for intermediate and advanced stages.Consequently,different additional scoring systems have been proposed to refine the prognosis and/or to improve the management.But until now,there is no consensus.Liu et al proposes a new scoring system,based on a large HCC cohort,with patients at different stages,treated using diverse modalities.This score includes six parameters used in current practice.It is simple to calculate,reliable,with an ability to predict survival superior to other systems,which also works with our European HCC cohort.The MESH score may be especially useful to differentiate subgroups with different prognosis for each treatment modality. | Xavier Adhoute Guillaume Pénaranda Jean-Luc Raoul Marc Bourlière | 2017 | World Journal of Hepatology2017，9，15： | 0 |
| 17 | Expected outcomes and patients’selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict”scores may help clinicians:Real-life French cohorts results显示文摘BACKGROUND Careful selection of hepatocellular carcinoma(HCC)patients prior to chemoembolization treatment is a daily reality,and is even more necessary with new available therapeutic options in HCC.To propose two new models to better stratify patients and maximize clinical benefit:“6 and 12”and“pre/post-TACE-predict”(TACE,transarterial chemoembolization).METHODS We evaluated and compared their performance in predicting overall survival with other systems{Barcelona Clinic Liver Cancer(BCLC),Albumin-Bilirubin(ALBI)and NIACE[Number of tumor(s),Infiltrative HCC,alpha-fetoprotein,Child-Pugh(CP),and performance status]}in two HCC French cohorts of different stages enrolled between 2010 and 2018.RESULTS The cohorts included 324 patients classified as BCLC stages A/B(cohort 1)and 137 patients classified as BCLC stages B/C(cohort 2).The majority of the patients had cirrhosis with preserved liver function.“Pre-TACE-predict”and“6 and 12”models identified three distinct categories of patients exhibiting different prognosis in cohort 1.However,their prognostic value was no better than the BCLC system or NIACE score.Liver function based on CP and ALBI grades significantly impacted patient survival.Conversely,the“post-TACE-predict”model had a higher predictive value than other models.The stratification ability as well as predictive performance of these new models in an intermediate/advanced stage population was less efficient(cohort 2).CONCLUSION The newly proposed“Pre-TACE-predict”and“6 and 12”models offer an interesting stratification into three categories in a recommended TACE population,as they identify poor candidates,those with partial control and durable response.The models'contribution was reduced in a population with advanced stage HCCs. | Xavier Adhoute Edouard Larrey Rodolphe Anty Patrick Chevallier Guillaume Penaranda Albert Tran Jean-Pierre Bronowicki Jean-Luc Raoul Paul Castellani HervéPerrier Olivier Bayle Olivier Monnet Bernard Pol Marc Bourliere | 2021 | World Journal of Clinical Cases2021，9，18： | 0 |
| 18 | Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma:Real-life Data on Liver Disease,Treatment and Prognosis显示文摘Background and Aims:Hepatocellular carcinoma(HCC)and intrahepatic cholangiocarcinoma(iCCA)have common features and differences.This real-life study investigated their characteristics,treatment modalities,and prognoses.Methods:This retrospective comparative study was performed in 1,075 patients seen at one tertiary center between January 2008 and December 2020.Overall survival(OS)was estimated by the Kaplan-Meier method.Subclassification of iCCAs after histological and radiological review,and molecular profiling was performed.Results:HCCs patients were more likely to have early-stage disease than iCCA patients.iCCA patients were more likely to be female,especially those patients without cirrhosis(43%vs.17%).Cirrhosis was prominent among HCC patients(89%vs.34%),but no difference in underlying liver disease among cirrhotic patients was found.OS of HCC patients was 18.4(95%CI:6.4,48.3)months,that of iCCA patients was 7.0(95%CI:3.4,20.1)months.OS of Barcelona Clinic Liver Cancer C HCC patients was 7.8(95%CI:4.3,14.2)months,that of advanced/metastatic iCCA patients was 8.5(95%CI:5.7,12.3)months.In patients treated with sorafenib,OS was longer in HCC patients who received subsequent tyrosine kinase inhibitor therapies.No significant OS difference was found between iCCA patients with and without cirrhosis or according to histological subtype.A targetable molecular alteration was detected in 50%of the iCCA patients.Conclusions:In this French series,cirrhosis was common in iCCA,which showed etiological factors comparable to those of HCC,implying a distinct oncogenic pathway.Both entities had a dismal prognosis at advanced stages.However,systemic therapies sequencing in HCC and molecular profiling in iCCA offer new insights. | Xavier Adhoute Olivia Pietri Guillaume Pénaranda Thomas Wolf Patrick Beaurain Olivier Monnet Arthur Laquière Justine Bonomini Frédéric Neumann Olivier Levrel Jean-Pascal Buono Xavier Hanna Paul Castellani HervéPerrier Marc Bourliere Rodolphe Anty | 2023 | Journal of Clinical and Translational Hepatology2023，11，5： | 0 |
| 19 | “Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort显示文摘The“six-and-twelve”(6&12)score is a new hepatocellular carcinoma(HCC)prognostic index designed for recommended transarterial chemoembolization(TACE)candidates.Quick and easy to use by the sum of tumor size(cm)and number,this model identifies three groups with different survival time(the sum is≤6;or>6 but≤12;or>12);a survival benefit with TACE can be expected for HCC patients with a score not exceeding twelve.Recently,Wang ZW et al showed that the“6&12”model was the best system correlated with radiological response after the first TACE.Thus,we wanted to assess its survival prediction ability as well as its prognostic value and compared it to other systems(Barcelona Clinic Liver Cancer,Hong Kong Liver Cancer(HKLC)staging,Albumin-Bilirubin grade,tumor nodularity,infiltrative nature of the tumor,alpha-fetoprotein,Child-Pugh class,and Performance Status score,Cancer of the Liver Italian Program,Model to Estimate Survival for HCC scores,up-to-seven criteria)different from Wang ZW et al study in a multicenter French cohort of HCC including only recommended TACE candidates retrospectively enrolled.As previously demonstrated,we show that the'6&12”score can classify survival within this French cohort,with a prognostic value comparable to that of other systems,except HKLC staging.More importantly,the“6&12”score simplicity and ability in patients’stratification outperform other systems for a routine clinical practice. | Xavier Adhoute Guillaume Pénaranda Jean-Luc Raoul Jean-Pierre Bronowicki Rodolphe Anty MarcBourlière | 2020 | World Journal of Hepatology2020，12，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员